MRM Health has received clearance from the FDA for its IND application, enabling the company to start the STARFISH-UC Phase ...

BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

These results tout the potential Eli Lilly's Taltz-Zepbound as the new SoC for PsA patients with comorbid obesity.

The Mount Sinai TCC has introduced an AI clinical trial matching platform, PRISM, to improve access to cancer research ...

In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.

Medical Devices includes a session from a regulatory expert on how companies can align their research between regions.

Treatment with the tumour necrosis factor receptor 2 (TNFR2)-targeting monoclonal antibody (mAb) plus Keytruda was also found ...